Home  >  Products  >  CLN6 (ceroid-lipofuscinosis, neuronal 6, late infantile, variant) Blocking Peptide (the C terminal of protein) (100ug)
CLN6 (ceroid-lipofuscinosis, neuronal 6, late infantile, variant) Blocking Peptide (the C terminal of protein) (100ug)

CLN6 (ceroid-lipofuscinosis, neuronal 6, late infantile, variant) Blocking Peptide (the C terminal of protein) (100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-CLN6 antibody (Catalogue #: ARP47372_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Presku: AAP47372
Size: 100 ug
Weight: 36kDa
Gene: 54982
Format: Lyophilized powder
Target: CLN6 is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely CLN6 involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.
Alternative names: FLJ20561; HsT18960; nclf
See Full Product Listings >